Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 1/20 | 0.50 |
| ▸ | BCL9 | O00512 | 4/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | F10 | P00742 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662869 | 0.92 | PTGER2 (0.52) | PTGER2BCL9CTNNB1MAPTF10 | |
| SCHEMBL3660760 | 0.87 | ALDH1A1 (0.55) | PTGER2MAPTF10LMNASMN1; SMN2 | |
| SCHEMBL13190035 | 0.86 | PTGER2 (0.49) | PTGER2BCL9CTNNB1MAPTF10 | |
| SCHEMBL29781355 | 0.85 | PTGER2 (0.67) | PTGER2MAPTF10LMNASMN1; SMN2 | |
| SCHEMBL3062083 | 0.85 | PTGER2 (0.67) | PTGER2MAPTF10LMNASMN1; SMN2 | |
| SCHEMBL29372302 | 0.85 | PTGER2 (0.67) | PTGER2MAPTF10LMNASMN1; SMN2 | |
| SCHEMBL13063092 | 0.85 | PTGER2 (0.50) | PTGER2BCL9CTNNB1MAPTF10 | |
| SCHEMBL3050603 | 0.85 | PTGER2 (0.52) | PTGER2MAPTF10LMNASMN1; SMN2 | |
| SCHEMBL29781323 | 0.85 | PTGER2 (0.52) | PTGER2MAPTF10LMNASMN1; SMN2 | |
| SCHEMBL3661994 | 0.85 | PTGER2 (0.52) | PTGER2MAPTF10LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331410-A1 | Biaryl Amides | ASTERAND UK LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
| EP-2238101-A2 | DIFLUOROBIPHENYLAMIDE DERIVATIVES FOR THE TREATMENT OF OCULAR HYPERTENSION | ASTERAND UK LIMITED (GB) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009098458-A2 | BIARYL AMIDES | ASTERAND UK LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331410-A1 | Biaryl Amides | AGTR2, CYP11B2, ALDH1A2 | PTGER2 242/4885BCL9 3005/4885CTNNB1 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.